Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Empiriko, Interchim Sign Partnership Agreement

Published: Thursday, February 27, 2014
Last Updated: Thursday, February 27, 2014
Bookmark and Share
Empiriko will leverage Interchim's PuriFlash®/MassSpec technology to conduct in vitro and ex-vivo drug metabolism studies using its Biomimiks™ technology.

By leveraging the powerful combination of Empiriko's game-changing chemosynthetic livers and Interchim's innovative instrumentation and expertise in the field of liquid chromatography, pharmaceutical scientists can now predict metabolism patterns, pathways and profiles -- all while generating a complete spectrum of oxidative metabolites for specific drugs and reducing the time for each experiment from weeks to hours. Additionally, scientists and clinicians can quickly identify interactions involving metabolite attenuation and suppression, and evaluate the genotoxicity, drug-to-drug interactions and efficacy associated with adding a new drug to a patient's drug regimen. Interchim's latest PuriFlash® instruments incorporate a mass spectrometer which allows near real-time product separation and structural elucidation of purified compounds and is ideally suited to support Empiriko's Biomimiks technology.

"Our partnership with Interchim represents an important step forward for both companies," said Mukund Chorghade, Empiriko's Chief Scientific Officer. "We are able to offer more comprehensive drug discovery and clinical research solutions and results. Together we will accelerate the delineation of metabolism profiles, enable prediction and scale-up of products and offer scientists a valuable tool for rapid separation and quantification of products. We look forward to working with Interchim to advance the boundaries of DMPK studies."

Also under the agreement, Empiriko will provide input to Interchim with regard to the design of future instrumentation for ex-vivo studies geared toward personalized patient treatment. Empiriko's unprecedented approach to drug testing will drive efficiencies and cost savings, helping pharmaceutical companies realize the next generation of discoveries.

"In a manner of minutes, we were able to generate and isolate metabolites for pharmaceutical entities using Empiriko's Biomimiks™ catalyst and our PuriFlash instrument," added Geoff Todosiev, President of Interchim, Inc. "It was remarkable to observe our instruments being used in such an innovative manner. This partnership opens a whole new market for Interchim's instruments to be used in new applications and we're excited about our ongoing work together."

"Pharmaceutical companies are eager to propel advances in drug discovery and clinical development under continued budget and timeline constraints, and we're determined to help alleviate these top challenges," said Pam Randhawa, Empiriko's CEO. "Interchim's technology will play an important role in helping us fulfill our vision throughout the entire drug lifecycle -- evaluating new chemical entities for drug discovery and clinical trials, as well as personalized patient treatment. No doubt we are working under a new paradigm -- and it is an incredibly exciting time."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Fight Against Fungal Infections
A pioneering university research team has recently employed such a system within their laboratory to obtain a greater understanding of the dynamics and progression of C. albicans in vivo using a mouse model.
Fly Study into Therapies for HVP-Induced Cancer
Fruit flies may help scientists understand the mechanism by which HPV can cause cancer as well as identify potential drug treatments.
Exploring Ebola-Malaria Link
Data shows people infected with Ebola were more likely to survive if co-infected with malarial parasite.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
Characterizing the Mouse Gut Microbiome
Study establishes the first public collection of bacteria from the intestine of mice.
Common Drug Shows Potential as Alzheimer's Cure
A research project has shown that an experimental model of Alzheimer’s disease can be successfully treated with a commonly used anti-inflammatory drug.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Magnetic Drug Delivery in the Body
Imagine a device that could transport drugs to any diseased site in the body with the help of a small magnet.
The Power of Model Systems
New insights into the influence of host on the gut microbiome are revealed with in situ light sheet fluorescence microscopy and stochastic mathematical modelling.
Using Animal Embryos Containing Human Cells
With recent advances in stem cell and gene editing technologies, an increasing number of researchers are interested in growing human tissues and organs in animals by introducing pluripotent human cells into early animal embryos.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!